Reflection paper on the dissolution specification for ...
1.1. Scope In the context of this reflection paper immediate release is identified as at least 75% (Q) of the active substance is dissolved within 45 minutes.
Download Reflection paper on the dissolution specification for ...
Information
Domain:
Source:
Link to this page:
Documents from same domain
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Related documents
fDA Guidance for Industry Dissolution Testing of …
www.dissolutiontech.comfDA Guidance for Industry 1 Dissolution Testing of Immediate Release Solid Oral Dosage forms 7iJis gllidl/I/ce is df'lleloped jar immedil/Ie "lease (lR) dosl/ge j017I1S I/Ild is illtrnded 10 prrruide (/) gel/eml
Physicochemical Properties of Buffers Used in …
www.dissolutiontech.com38 AUUST 2017 T INTRODUCTION he pH of buffered dissolution media is a singularly important parameter for dissolution testing because pH influences drug solubility and dissolution rate (1).
Guideline on non-clinical local tolerance testing of ...
www.ema.europa.euGuideline on non-clinical local tolerance testing of medicinal products EMA/CHMP/SWP/2145/2000 Rev. 1 Page 2/9 Guideline on non-clinical local tolerance testing of
ORIGINAL ARTICLE FORMULATION AND IN VITRO …
www.revistafarmacia.rofarmacia, 2015, vol. 63, 1 111 original article formulation and in vitro release testing of rectal suppositories containing nimesulide anca cecilia nicoarĂ1, radu george cazacincu2*, dumitru lupuleasa1, dalia
Methodological considerations: Potency tests for ...
www.who.intMethodological considerations: Potency tests for recombinant adjuvanted RTS,S vaccine Background Adjuvanted recombinant RTS,S-based vaccines have been in clinical evaluation since the late